LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
Rhea-AI Summary
LeonaBio (NASDAQ:LONA) will present at two June 2026 industry meetings. The company will give an oral presentation on ATH-1105 in ALS at the 5th Annual ALS Drug Development Summit and join an oncology trials panel at the BIO International Convention.
Positive
- None.
Negative
- None.
News Market Reaction – LONA
In the May 27 session, LONA gained 1.45%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.9% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.
Details are as follows:
5th Annual ALS Drug Development Summit
Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies
Session Title: Redefining Biomarkers and Trial Design to Accelerate Neurodegenerative Disease Therapies
Presenter: Javier San Martin, M.D., Chief Medical Officer, LeonaBio
Presentation Date and Time: Wednesday, June 3, 2026, at 2:50 p.m. ET
Location: The Colonnade Hotel, Boston, MA
BIO International Convention
Panel Presentation Title: The Future of Oncology Trials: Aligning Science, Regulation, and Investment in Overall Survival
Presenter: David Portman, M.D., Chief Executive Officer, Sermonix; Oncology Consultant, LeonaBio
Panel Date and Time: Wednesday, June 24, 2026, at 11:00 a.m. PT
Location: Room 32AB, San Diego Convention Center, San Diego, CA
About LeonaBio
LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.
For more information, visit www.leonabio.com.
Investor & Media Contact:
Julie Rathbun
LeonaBio
Julie.rathburn@leonabio.com
206-769-9219
